Immutep Says Have Sufficient Cash to Fund Operations into 2023
02:47 PM EDT, 05/07/2021 (MT Newswires) -- Immutep (IMMP) said it has enough cash to fund operations into 2023, which is beyond the expected timing for a range of "significant data read-outs" from its trials.
The Australia-based biotech group added that it is on track to report final overall survival data from its Phase 2b clinical trial of its drug candidate, Eftilagimod alpha, for the treatment of metastatic breast cancer during H2.
Eftilagimod alpha has been granted fast-track designation by the US Food and Drug Administration for first line recurrent or metastatic head and neck squamous cell carcinoma.
Price: 3.44, Change: +0.24, Percent Change: +7.50